Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release. The headline results from ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NVO's Novel Obesity Treatment Disappoints in Phase III Study Novo Nordisk's phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint.

The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial ... "2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly," the maximum dosage of CagriSema contemplated by ...

that gave a weight reduction of 22.7% for CagriSema versus 11.8% with cagrilintide alone, 16.1% with semaglutide, and 2.3% with placebo. The design of REDEFINE-1 allowed patients to lower their ...